Postoperative Care and Management in Pediatric Hematology‑Oncology Patients
This review provides a comprehensive overview of common pediatric hemato‑oncologic surgeries and detailed postoperative management strategies. A thorough, multidisciplinary postoperative plan is essential for pediatric hematology‑oncology patients to minimize morbidity, avoid delays in adjuvant therapy, and ultimately enhance survival and quality of life.
Pediatric patients with hematologic and oncologic diseases often undergo surgical procedures as part of diagnosis and therapy. These include central venous catheter placements, tumor resections, lymph node and bone marrow biopsies, among others. Optimal postoperative care in this vulnerable population is critical, as children receiving chemotherapy or stem cell transplantation are immunocompromised and at high risk for infections, bleeding, and other complications. This review provides a comprehensive overview of common pediatric hemato‑oncologic surgeries and detailed postoperative management strategies. A thorough, multidisciplinary postoperative plan is essential for pediatric hematology‑oncology patients to minimize morbidity, avoid delays in adjuvant therapy, and ultimately enhance survival and quality of life.
Pediatric oncology patients are immunocompromised and at high risk for postoperative complications; effective postoperative care can prevent morbidity, avoid treatment delays, and improve survival and quality of life.
Evidence level: Számítógépes vagy elméleti. Modellből vagy adatbányászatból származó jel.
Related signals
- Quercetin suppresses the progression of HBV-associated hepatocellular carcinoma by modulating the EGFR signaling pathway
- Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial
- Surgical treatment of hepatocellular carcinoma: expert consensus statement
- Loco-regional treatment of hepatocellular carcinoma
- Real‑World Outcomes of Atezolizumab‑Bevacizumab in Hepatocellular Carcinoma: The Prospective French CHIEF Cohort